One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISH
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial
Interpreting the ODYSSEY-HCM Secondary Analyses: Biological Signals, Clinical Silence
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM
First-Line Therapy for Hypertrophic Cardiomyopathy: Can’t Teach the Old Dogma New Tricks
Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR
Tricuspid Regurgitation Across the Spectrum of Heart Failure With Preserved Ejection Fraction
Tricuspid Regurgitation in HFpEF: A Window Into Disease Progression and Phenotypic Complexity
Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis
Beyond the 4 Pillars: Where Does Vericiguat Stand in Contemporary HFrEF Care?
Characteristics and Long-Term Outcomes of Asymptomatic Patients With Hypertrophic Cardiomyopathy
Amara Yad Image: 2-Chamber View of the Left Heart—Lateral Segment
